SlideShare a Scribd company logo
Mohammad Asim +919953194659
COMMON TECHNICAL DOCUMENT (CTD)
Substantial documentation and data are required in submissions for import/manufacture and marketing
approval of drugs for human use, resulting in large, complex applications. Till date, applicants have used many
different approaches in organizing the information and the differences in organization of data in each
application has made reviewing more difficult and can also lead to omission of critical data or analyses. Such
omissions can result in unnecessary delays in approvals. Thus, a common format of submission will help in
overcoming these hurdles.
The CTD is a set of specifications for a dossier for the registration of medicines (TGA) CTD is an internationally
agreed “well-structured common format” for the organization of the technical requirements that is to be
submitted to the regulatory authority as an application for the registration of pharmaceuticals for human use
in all three ICH regions (U.S.A., Europe and Japan).
In 2000, the 10th Anniversary of ICH, Dr. Caroline Nutley Loew of the Pharmaceutical Research and
Manufacturers of America (PhRMA) wrote a report, The Value and Benefits of ICH to Industry, which detailed
ICH’s creation, procedures, and guideline development in the areas of safety, efficacy, and quality. Her report
anticipated that the CTD would revolutionize the submission procedures for industry’s regulatory staff. Dr.
Loew characterized the CTD as “offering potential benefits to industry far greater than any other single ICH
topic,” and predicted the CTD would afford significant savings in time and resources as complex multiple
submissions were replaced by a single technical dossier submitted in the three ICH regions— 13 facilitating
simultaneous submission, approval, and launch of new drugs.
In calling the CTD “a topic whose value to industry cannot be underestimated,” Dr. Loew noted that with full
incorporation of the CTD and the electronic CTD (eCTD), ICH could turn its sights to disseminating guideline
information to non- ICH countries, yielding additional benefits to both regulators and industry. Ten years later
and in anticipation of ICH’s 20th Anniversary, the value and benefits of ICH to regulators have been realized.
Mohammad Asim +919953194659
The primary objective of the ICH is to avoid duplicative animal and human testing and to reach a common
understanding of the technical requirements to support the registration process in the three ICH regions.
These objectives are achieved through harmonized guidelines and result in a more economical use of human,
animal and material resources, as well as the elimination of unnecessary delays in the global development and
availability of new medicines, whilst maintaining safeguards on quality, safety and efficacy, and regulatory
obligations to protect public health. With the development of the Common Technical Document (CTD), the ICH
hopes to accomplish many of its objectives.
It is organized into:
Module 1: General Information
Module 2: CTD summaries
Module 3: Quality
Module 4: Nonclinical study reports
Module 5: Clinical study reports
MODULE 1
Administrative information and prescribing information. Document specific to each region. E.g. Application
form
Proposed label for use in the region
Mohammad Asim +919953194659
MODULE 3 QUALITY
The Quality section of the Common Technical Document (M4Q) provides a harmonized structure and
format for presenting CMC (Chemistry, Manufacturing and Controls) information in a registration dossier.
Module 3 content
3.1 Module 3 table of contents
3.2 Body of data
3.3 Literature references
MODULE 4: NON-CLINICAL STUDY REPORTS
Module 4 describes the format and organization of the nonclinical (pharmaco-toxicological) data
relevant to the application.
4.2 STUDY REPORTS
4.2.1 Pharmacology
4.2.2 Pharmacokinetics
4.2.3 Toxicology
4.3 literature references
MODULE 5: CLINICAL STUDY REPORTS
Module 5 describes the format and organization of the clinical data relevant to the application. 5.3.1
Reports of Biopharmaceutical Studies
5.3.2 Reports of Studies Pertinent to Pharmacokinetics Using Human Biomaterials
5.3.3 Reports of Human Pharmacokinetic (PK) Studies
5.3.4 Reports of Human Pharmacodynamic (PD) Studies
5.3.5 Reports of Efficacy and Safety Studies
5.3.6 Reports of Post-Marketing Experience
5.3.7 Case Report Forms and Individual Patient Listings
5.4 literature references
Mohammad Asim +919953194659
ECTD: ELECTRONIC – CTD
Developed by M2 EWG (Multidisciplinary 2 Expert Working Group) of ICH. Paper submission has been replaced
by electronic submission.
CHARACTERISTICS OF ECTD:
1. Files Referenced in the XML Backbone(s) (Extensible Markup Language)
REASONS:
a) It manages the large data for the entire submission and for each document within the submission.
b) This XML backbone allows the eCTD submission to be viewed via a web browser and can be loaded
on a Web server.
2. The file formats that can be included in the eCTD are Portable Document Format (PDF) and XML.
However other formats can be used for graphs and images. JPEG PNG GIF -may be used for higher
resolution.
3. All eCTD submissions include module 1.
ADVANTAGES OF CTD
 To make the reviewing of each application easier and also to avoid omission of critical data or
analyses.
 Omissions of such data can result in unnecessary delays in approvals.
 To save time and resources.
 To facilitate regulatory review and communications.
 Appropriate format for the data
 Easy to understand and evaluation of data.
SILENT BENEFITS OF THE CTD
 More “reviewable” applications
 Complete, well-organized submissions
 More predictable format
 More consistent reviews
 Easier analysis across applications
 Easier exchange of information
 Facilitates electronic submissions
LIMITATIONS
 CTD is only a format, it’s not a single dossier with a single content.
 Legal requirements differ in the different regions.
 ICH guidelines have not yet harmonized in all requirements.
 Pharmacopoeias are not harmonized Applicant may have regional preferences.

More Related Content

What's hot

NSF certification, Standard for dietary supplement
NSF certification, Standard for dietary supplementNSF certification, Standard for dietary supplement
NSF certification, Standard for dietary supplement
Atul Bhombe
 
EU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONSEU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONS
Chandra Mohan
 
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
sandeep bansal
 
CTD and eCTD - Common Technical Document
CTD and eCTD - Common Technical DocumentCTD and eCTD - Common Technical Document
CTD and eCTD - Common Technical Document
Darewin Mendonsa
 
DMF CEP
DMF CEPDMF CEP
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
indus university-icri
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptx
NikhilBorade5
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairs
KusumaLathaBeera1
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
Doninder Hooda
 
An introduction to the EMA
An introduction to the EMAAn introduction to the EMA
An introduction to the EMA
EURORDIS Rare Diseases Europe
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
datchayani
 
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPANMEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
DeveshDRA
 
ACTD- ASEAN
ACTD- ASEANACTD- ASEAN
ACTD- ASEAN
Naila Kanwal
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
RajaniKarpur
 
Nsf standard
Nsf standardNsf standard
Nsf standard
Rx vidhi Ramani
 
ACTD Guidelines Overview
ACTD Guidelines OverviewACTD Guidelines Overview
ACTD Guidelines Overview
Muhammad Ali Jehangir
 
Orange book
Orange bookOrange book
Orange book
Rucha Pathak
 
ctd and e ctd submission
ctd and e ctd submissionctd and e ctd submission
ctd and e ctd submission
Rohit K.
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.
Rovil Goel
 
The Electronic Regulatory Submission
The Electronic Regulatory SubmissionThe Electronic Regulatory Submission
The Electronic Regulatory Submission
Dr.RAJEEV KASHYAP
 

What's hot (20)

NSF certification, Standard for dietary supplement
NSF certification, Standard for dietary supplementNSF certification, Standard for dietary supplement
NSF certification, Standard for dietary supplement
 
EU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONSEU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONS
 
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
 
CTD and eCTD - Common Technical Document
CTD and eCTD - Common Technical DocumentCTD and eCTD - Common Technical Document
CTD and eCTD - Common Technical Document
 
DMF CEP
DMF CEPDMF CEP
DMF CEP
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptx
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairs
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
 
An introduction to the EMA
An introduction to the EMAAn introduction to the EMA
An introduction to the EMA
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
 
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPANMEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
 
ACTD- ASEAN
ACTD- ASEANACTD- ASEAN
ACTD- ASEAN
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
 
Nsf standard
Nsf standardNsf standard
Nsf standard
 
ACTD Guidelines Overview
ACTD Guidelines OverviewACTD Guidelines Overview
ACTD Guidelines Overview
 
Orange book
Orange bookOrange book
Orange book
 
ctd and e ctd submission
ctd and e ctd submissionctd and e ctd submission
ctd and e ctd submission
 
Organizaton chart of us fda.
Organizaton chart of us fda.Organizaton chart of us fda.
Organizaton chart of us fda.
 
The Electronic Regulatory Submission
The Electronic Regulatory SubmissionThe Electronic Regulatory Submission
The Electronic Regulatory Submission
 

Similar to Common technical document (CTD) and electronic common technical document (eCTD)

CTD & ECTD
CTD & ECTDCTD & ECTD
CTD & ECTD
Suvarta Maru
 
Ctd and ectd m pharmacy notes scop satara
Ctd and ectd  m pharmacy notes scop sataraCtd and ectd  m pharmacy notes scop satara
Ctd and ectd m pharmacy notes scop satara
nikhil salunkhe
 
121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx
TridevSastri1
 
CTD & ectd.pptx
CTD & ectd.pptxCTD & ectd.pptx
CTD & ectd.pptx
RizwanAhmad812370
 
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPERCTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
InthiyazBegum
 
CTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsCTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory Affairs
Dipesh Gosavi
 
CTD & E-CTD
CTD & E-CTDCTD & E-CTD
CTD & E-CTD
Apoorva Bauskar
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
BishalBhattacharjee11
 
CTD AND ECTD
CTD AND ECTDCTD AND ECTD
CTD AND ECTD
ROHIT
 
CTD and eCTD.pptx
CTD and eCTD.pptxCTD and eCTD.pptx
CTD and eCTD.pptx
GauravPanchal55
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
Dr Sukanta sen
 
CTD and ECTD by Akshay Trivedi
CTD and ECTD by Akshay TrivediCTD and ECTD by Akshay Trivedi
CTD and ECTD by Akshay Trivedi
Akshay Trivedi , Maliba Pharmacy College
 
CTD and eCTD
CTD and eCTDCTD and eCTD
CTD and eCTD
Madhavi Gupta
 
CTD (common technical document)
CTD (common technical document)CTD (common technical document)
CTD (common technical document)
Dr. Jigar Vyas
 
Ctd and e ctd
Ctd and e ctdCtd and e ctd
Ctd and e ctd
Sayeda Salma S.A.
 
final semiar ppt
final semiar pptfinal semiar ppt
final semiar ppt
neraja reddi amaram
 
CTD and eCTD Format
CTD and eCTD Format CTD and eCTD Format
CTD and eCTD Format
NikhilThorane
 
eCTD.pptx
eCTD.pptxeCTD.pptx
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
Tanmay Madhavi
 
Common technical Documents For B.Pharm, M.pharm
Common technical Documents For B.Pharm, M.pharmCommon technical Documents For B.Pharm, M.pharm
Common technical Documents For B.Pharm, M.pharm
AkankshaGadekar4
 

Similar to Common technical document (CTD) and electronic common technical document (eCTD) (20)

CTD & ECTD
CTD & ECTDCTD & ECTD
CTD & ECTD
 
Ctd and ectd m pharmacy notes scop satara
Ctd and ectd  m pharmacy notes scop sataraCtd and ectd  m pharmacy notes scop satara
Ctd and ectd m pharmacy notes scop satara
 
121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx121725101010-CTDandeCTD.pptx
121725101010-CTDandeCTD.pptx
 
CTD & ectd.pptx
CTD & ectd.pptxCTD & ectd.pptx
CTD & ectd.pptx
 
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPERCTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
 
CTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsCTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory Affairs
 
CTD & E-CTD
CTD & E-CTDCTD & E-CTD
CTD & E-CTD
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
 
CTD AND ECTD
CTD AND ECTDCTD AND ECTD
CTD AND ECTD
 
CTD and eCTD.pptx
CTD and eCTD.pptxCTD and eCTD.pptx
CTD and eCTD.pptx
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
 
CTD and ECTD by Akshay Trivedi
CTD and ECTD by Akshay TrivediCTD and ECTD by Akshay Trivedi
CTD and ECTD by Akshay Trivedi
 
CTD and eCTD
CTD and eCTDCTD and eCTD
CTD and eCTD
 
CTD (common technical document)
CTD (common technical document)CTD (common technical document)
CTD (common technical document)
 
Ctd and e ctd
Ctd and e ctdCtd and e ctd
Ctd and e ctd
 
final semiar ppt
final semiar pptfinal semiar ppt
final semiar ppt
 
CTD and eCTD Format
CTD and eCTD Format CTD and eCTD Format
CTD and eCTD Format
 
eCTD.pptx
eCTD.pptxeCTD.pptx
eCTD.pptx
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
 
Common technical Documents For B.Pharm, M.pharm
Common technical Documents For B.Pharm, M.pharmCommon technical Documents For B.Pharm, M.pharm
Common technical Documents For B.Pharm, M.pharm
 

More from MOHAMMAD ASIM

Introduction to Affinity Chromatography
Introduction to Affinity ChromatographyIntroduction to Affinity Chromatography
Introduction to Affinity Chromatography
MOHAMMAD ASIM
 
Dissolution parameters of a dosage form
Dissolution parameters of a dosage formDissolution parameters of a dosage form
Dissolution parameters of a dosage form
MOHAMMAD ASIM
 
Vaccine Delivery System
Vaccine Delivery SystemVaccine Delivery System
Vaccine Delivery System
MOHAMMAD ASIM
 
3 D printing technology in pharmaceutical drug delivery system
3 D printing technology in pharmaceutical drug delivery system3 D printing technology in pharmaceutical drug delivery system
3 D printing technology in pharmaceutical drug delivery system
MOHAMMAD ASIM
 
Barriers to Ocular Drug Delivery
Barriers to Ocular Drug DeliveryBarriers to Ocular Drug Delivery
Barriers to Ocular Drug Delivery
MOHAMMAD ASIM
 
Introduction to Telepharmacy
Introduction to TelepharmacyIntroduction to Telepharmacy
Introduction to Telepharmacy
MOHAMMAD ASIM
 
Buccal Drug Delivery System
Buccal Drug Delivery SystemBuccal Drug Delivery System
Buccal Drug Delivery System
MOHAMMAD ASIM
 
Ethosomes: formulation and particle size determination
Ethosomes: formulation and particle size determinationEthosomes: formulation and particle size determination
Ethosomes: formulation and particle size determination
MOHAMMAD ASIM
 
Biopharmaceutic considerations in drug product design
Biopharmaceutic considerations in drug product designBiopharmaceutic considerations in drug product design
Biopharmaceutic considerations in drug product design
MOHAMMAD ASIM
 
Computer simulation in pharmacokinetics and pharmacodynamics
Computer simulation in pharmacokinetics and pharmacodynamicsComputer simulation in pharmacokinetics and pharmacodynamics
Computer simulation in pharmacokinetics and pharmacodynamics
MOHAMMAD ASIM
 
Ethosomes - formulation and evaluation
Ethosomes - formulation and evaluationEthosomes - formulation and evaluation
Ethosomes - formulation and evaluation
MOHAMMAD ASIM
 
Clinical data collection and management
Clinical data collection and managementClinical data collection and management
Clinical data collection and management
MOHAMMAD ASIM
 
Microcapsules: types, preparation and evaluation
Microcapsules: types, preparation and evaluationMicrocapsules: types, preparation and evaluation
Microcapsules: types, preparation and evaluation
MOHAMMAD ASIM
 
Cosmetics - Biological aspects and design of cosmeceutical products
Cosmetics - Biological aspects and design of cosmeceutical productsCosmetics - Biological aspects and design of cosmeceutical products
Cosmetics - Biological aspects and design of cosmeceutical products
MOHAMMAD ASIM
 
Biosimilars and regulatory requirements for approval.
Biosimilars and regulatory requirements for approval.Biosimilars and regulatory requirements for approval.
Biosimilars and regulatory requirements for approval.
MOHAMMAD ASIM
 
Hair structure and hair growth cycle
Hair structure and hair growth cycleHair structure and hair growth cycle
Hair structure and hair growth cycle
MOHAMMAD ASIM
 
Common ingredients used in cosmetics
Common ingredients used in cosmeticsCommon ingredients used in cosmetics
Common ingredients used in cosmetics
MOHAMMAD ASIM
 
institutional review board and independent ethics committee
institutional review board and independent ethics committeeinstitutional review board and independent ethics committee
institutional review board and independent ethics committee
MOHAMMAD ASIM
 

More from MOHAMMAD ASIM (18)

Introduction to Affinity Chromatography
Introduction to Affinity ChromatographyIntroduction to Affinity Chromatography
Introduction to Affinity Chromatography
 
Dissolution parameters of a dosage form
Dissolution parameters of a dosage formDissolution parameters of a dosage form
Dissolution parameters of a dosage form
 
Vaccine Delivery System
Vaccine Delivery SystemVaccine Delivery System
Vaccine Delivery System
 
3 D printing technology in pharmaceutical drug delivery system
3 D printing technology in pharmaceutical drug delivery system3 D printing technology in pharmaceutical drug delivery system
3 D printing technology in pharmaceutical drug delivery system
 
Barriers to Ocular Drug Delivery
Barriers to Ocular Drug DeliveryBarriers to Ocular Drug Delivery
Barriers to Ocular Drug Delivery
 
Introduction to Telepharmacy
Introduction to TelepharmacyIntroduction to Telepharmacy
Introduction to Telepharmacy
 
Buccal Drug Delivery System
Buccal Drug Delivery SystemBuccal Drug Delivery System
Buccal Drug Delivery System
 
Ethosomes: formulation and particle size determination
Ethosomes: formulation and particle size determinationEthosomes: formulation and particle size determination
Ethosomes: formulation and particle size determination
 
Biopharmaceutic considerations in drug product design
Biopharmaceutic considerations in drug product designBiopharmaceutic considerations in drug product design
Biopharmaceutic considerations in drug product design
 
Computer simulation in pharmacokinetics and pharmacodynamics
Computer simulation in pharmacokinetics and pharmacodynamicsComputer simulation in pharmacokinetics and pharmacodynamics
Computer simulation in pharmacokinetics and pharmacodynamics
 
Ethosomes - formulation and evaluation
Ethosomes - formulation and evaluationEthosomes - formulation and evaluation
Ethosomes - formulation and evaluation
 
Clinical data collection and management
Clinical data collection and managementClinical data collection and management
Clinical data collection and management
 
Microcapsules: types, preparation and evaluation
Microcapsules: types, preparation and evaluationMicrocapsules: types, preparation and evaluation
Microcapsules: types, preparation and evaluation
 
Cosmetics - Biological aspects and design of cosmeceutical products
Cosmetics - Biological aspects and design of cosmeceutical productsCosmetics - Biological aspects and design of cosmeceutical products
Cosmetics - Biological aspects and design of cosmeceutical products
 
Biosimilars and regulatory requirements for approval.
Biosimilars and regulatory requirements for approval.Biosimilars and regulatory requirements for approval.
Biosimilars and regulatory requirements for approval.
 
Hair structure and hair growth cycle
Hair structure and hair growth cycleHair structure and hair growth cycle
Hair structure and hair growth cycle
 
Common ingredients used in cosmetics
Common ingredients used in cosmeticsCommon ingredients used in cosmetics
Common ingredients used in cosmetics
 
institutional review board and independent ethics committee
institutional review board and independent ethics committeeinstitutional review board and independent ethics committee
institutional review board and independent ethics committee
 

Recently uploaded

JavaScript Interview Questions PDF By ScholarHat
JavaScript Interview  Questions PDF By ScholarHatJavaScript Interview  Questions PDF By ScholarHat
JavaScript Interview Questions PDF By ScholarHat
Scholarhat
 
MVC Interview Questions PDF By ScholarHat
MVC Interview Questions PDF By ScholarHatMVC Interview Questions PDF By ScholarHat
MVC Interview Questions PDF By ScholarHat
Scholarhat
 
Genetics Teaching Plan: Dr.Kshirsagar R.V.
Genetics Teaching Plan: Dr.Kshirsagar R.V.Genetics Teaching Plan: Dr.Kshirsagar R.V.
Genetics Teaching Plan: Dr.Kshirsagar R.V.
DrRavindrakshirsagar1
 
Introduction to Google Productivity Tools for Office and Personal Use
Introduction to Google Productivity Tools for Office and Personal UseIntroduction to Google Productivity Tools for Office and Personal Use
Introduction to Google Productivity Tools for Office and Personal Use
Excellence Foundation for South Sudan
 
A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...
Association for Project Management
 
MathematicsGrade7-Presentation-July-12024.pptx
MathematicsGrade7-Presentation-July-12024.pptxMathematicsGrade7-Presentation-July-12024.pptx
MathematicsGrade7-Presentation-July-12024.pptx
nolicaliso1
 
FIRST AID PRESENTATION ON INDUSTRIAL SAFETY by dr lal.ppt
FIRST AID PRESENTATION ON INDUSTRIAL SAFETY by dr lal.pptFIRST AID PRESENTATION ON INDUSTRIAL SAFETY by dr lal.ppt
FIRST AID PRESENTATION ON INDUSTRIAL SAFETY by dr lal.ppt
ashutoshklal29
 
How to Manage Line Discount in Odoo 17 POS
How to Manage Line Discount in Odoo 17 POSHow to Manage Line Discount in Odoo 17 POS
How to Manage Line Discount in Odoo 17 POS
Celine George
 
Open Source and AI - ByWater Closing Keynote Presentation.pdf
Open Source and AI - ByWater Closing Keynote Presentation.pdfOpen Source and AI - ByWater Closing Keynote Presentation.pdf
Open Source and AI - ByWater Closing Keynote Presentation.pdf
Jessica Zairo
 
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
MANIVALANSR
 
11. Post harvest quality, Quality criteria and Judgement.pptx
11. Post harvest quality, Quality criteria and Judgement.pptx11. Post harvest quality, Quality criteria and Judgement.pptx
11. Post harvest quality, Quality criteria and Judgement.pptx
UmeshTimilsina1
 
Parkinson Disease & Anti-Parkinsonian Drugs.pptx
Parkinson Disease & Anti-Parkinsonian Drugs.pptxParkinson Disease & Anti-Parkinsonian Drugs.pptx
Parkinson Disease & Anti-Parkinsonian Drugs.pptx
AnujVishwakarma34
 
Node JS Interview Question PDF By ScholarHat
Node JS Interview Question PDF By ScholarHatNode JS Interview Question PDF By ScholarHat
Node JS Interview Question PDF By ScholarHat
Scholarhat
 
RDBMS Lecture Notes Unit4 chapter12 VIEW
RDBMS Lecture Notes Unit4 chapter12 VIEWRDBMS Lecture Notes Unit4 chapter12 VIEW
RDBMS Lecture Notes Unit4 chapter12 VIEW
Murugan Solaiyappan
 
3. Maturity_indices_of_fruits_and_vegetable.pptx
3. Maturity_indices_of_fruits_and_vegetable.pptx3. Maturity_indices_of_fruits_and_vegetable.pptx
3. Maturity_indices_of_fruits_and_vegetable.pptx
UmeshTimilsina1
 
How to Empty a One2Many Field in Odoo 17
How to Empty a One2Many Field in Odoo 17How to Empty a One2Many Field in Odoo 17
How to Empty a One2Many Field in Odoo 17
Celine George
 
Brigada Eskwela 2024 PowerPoint Update for SY 2024-2025
Brigada Eskwela 2024 PowerPoint Update for SY 2024-2025Brigada Eskwela 2024 PowerPoint Update for SY 2024-2025
Brigada Eskwela 2024 PowerPoint Update for SY 2024-2025
ALBERTHISOLER1
 
Parent PD Design for Professional Development .docx
Parent PD Design for Professional Development .docxParent PD Design for Professional Development .docx
Parent PD Design for Professional Development .docx
AntonioJarligoCompra
 
Odoo 17 Events - Attendees List Scanning
Odoo 17 Events - Attendees List ScanningOdoo 17 Events - Attendees List Scanning
Odoo 17 Events - Attendees List Scanning
Celine George
 
FINAL MATATAG Science CG 2023 Grades 3-10.pdf
FINAL MATATAG Science CG 2023 Grades 3-10.pdfFINAL MATATAG Science CG 2023 Grades 3-10.pdf
FINAL MATATAG Science CG 2023 Grades 3-10.pdf
maritescanete2
 

Recently uploaded (20)

JavaScript Interview Questions PDF By ScholarHat
JavaScript Interview  Questions PDF By ScholarHatJavaScript Interview  Questions PDF By ScholarHat
JavaScript Interview Questions PDF By ScholarHat
 
MVC Interview Questions PDF By ScholarHat
MVC Interview Questions PDF By ScholarHatMVC Interview Questions PDF By ScholarHat
MVC Interview Questions PDF By ScholarHat
 
Genetics Teaching Plan: Dr.Kshirsagar R.V.
Genetics Teaching Plan: Dr.Kshirsagar R.V.Genetics Teaching Plan: Dr.Kshirsagar R.V.
Genetics Teaching Plan: Dr.Kshirsagar R.V.
 
Introduction to Google Productivity Tools for Office and Personal Use
Introduction to Google Productivity Tools for Office and Personal UseIntroduction to Google Productivity Tools for Office and Personal Use
Introduction to Google Productivity Tools for Office and Personal Use
 
A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...
 
MathematicsGrade7-Presentation-July-12024.pptx
MathematicsGrade7-Presentation-July-12024.pptxMathematicsGrade7-Presentation-July-12024.pptx
MathematicsGrade7-Presentation-July-12024.pptx
 
FIRST AID PRESENTATION ON INDUSTRIAL SAFETY by dr lal.ppt
FIRST AID PRESENTATION ON INDUSTRIAL SAFETY by dr lal.pptFIRST AID PRESENTATION ON INDUSTRIAL SAFETY by dr lal.ppt
FIRST AID PRESENTATION ON INDUSTRIAL SAFETY by dr lal.ppt
 
How to Manage Line Discount in Odoo 17 POS
How to Manage Line Discount in Odoo 17 POSHow to Manage Line Discount in Odoo 17 POS
How to Manage Line Discount in Odoo 17 POS
 
Open Source and AI - ByWater Closing Keynote Presentation.pdf
Open Source and AI - ByWater Closing Keynote Presentation.pdfOpen Source and AI - ByWater Closing Keynote Presentation.pdf
Open Source and AI - ByWater Closing Keynote Presentation.pdf
 
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
 
11. Post harvest quality, Quality criteria and Judgement.pptx
11. Post harvest quality, Quality criteria and Judgement.pptx11. Post harvest quality, Quality criteria and Judgement.pptx
11. Post harvest quality, Quality criteria and Judgement.pptx
 
Parkinson Disease & Anti-Parkinsonian Drugs.pptx
Parkinson Disease & Anti-Parkinsonian Drugs.pptxParkinson Disease & Anti-Parkinsonian Drugs.pptx
Parkinson Disease & Anti-Parkinsonian Drugs.pptx
 
Node JS Interview Question PDF By ScholarHat
Node JS Interview Question PDF By ScholarHatNode JS Interview Question PDF By ScholarHat
Node JS Interview Question PDF By ScholarHat
 
RDBMS Lecture Notes Unit4 chapter12 VIEW
RDBMS Lecture Notes Unit4 chapter12 VIEWRDBMS Lecture Notes Unit4 chapter12 VIEW
RDBMS Lecture Notes Unit4 chapter12 VIEW
 
3. Maturity_indices_of_fruits_and_vegetable.pptx
3. Maturity_indices_of_fruits_and_vegetable.pptx3. Maturity_indices_of_fruits_and_vegetable.pptx
3. Maturity_indices_of_fruits_and_vegetable.pptx
 
How to Empty a One2Many Field in Odoo 17
How to Empty a One2Many Field in Odoo 17How to Empty a One2Many Field in Odoo 17
How to Empty a One2Many Field in Odoo 17
 
Brigada Eskwela 2024 PowerPoint Update for SY 2024-2025
Brigada Eskwela 2024 PowerPoint Update for SY 2024-2025Brigada Eskwela 2024 PowerPoint Update for SY 2024-2025
Brigada Eskwela 2024 PowerPoint Update for SY 2024-2025
 
Parent PD Design for Professional Development .docx
Parent PD Design for Professional Development .docxParent PD Design for Professional Development .docx
Parent PD Design for Professional Development .docx
 
Odoo 17 Events - Attendees List Scanning
Odoo 17 Events - Attendees List ScanningOdoo 17 Events - Attendees List Scanning
Odoo 17 Events - Attendees List Scanning
 
FINAL MATATAG Science CG 2023 Grades 3-10.pdf
FINAL MATATAG Science CG 2023 Grades 3-10.pdfFINAL MATATAG Science CG 2023 Grades 3-10.pdf
FINAL MATATAG Science CG 2023 Grades 3-10.pdf
 

Common technical document (CTD) and electronic common technical document (eCTD)

  • 1. Mohammad Asim +919953194659 COMMON TECHNICAL DOCUMENT (CTD) Substantial documentation and data are required in submissions for import/manufacture and marketing approval of drugs for human use, resulting in large, complex applications. Till date, applicants have used many different approaches in organizing the information and the differences in organization of data in each application has made reviewing more difficult and can also lead to omission of critical data or analyses. Such omissions can result in unnecessary delays in approvals. Thus, a common format of submission will help in overcoming these hurdles. The CTD is a set of specifications for a dossier for the registration of medicines (TGA) CTD is an internationally agreed “well-structured common format” for the organization of the technical requirements that is to be submitted to the regulatory authority as an application for the registration of pharmaceuticals for human use in all three ICH regions (U.S.A., Europe and Japan). In 2000, the 10th Anniversary of ICH, Dr. Caroline Nutley Loew of the Pharmaceutical Research and Manufacturers of America (PhRMA) wrote a report, The Value and Benefits of ICH to Industry, which detailed ICH’s creation, procedures, and guideline development in the areas of safety, efficacy, and quality. Her report anticipated that the CTD would revolutionize the submission procedures for industry’s regulatory staff. Dr. Loew characterized the CTD as “offering potential benefits to industry far greater than any other single ICH topic,” and predicted the CTD would afford significant savings in time and resources as complex multiple submissions were replaced by a single technical dossier submitted in the three ICH regions— 13 facilitating simultaneous submission, approval, and launch of new drugs. In calling the CTD “a topic whose value to industry cannot be underestimated,” Dr. Loew noted that with full incorporation of the CTD and the electronic CTD (eCTD), ICH could turn its sights to disseminating guideline information to non- ICH countries, yielding additional benefits to both regulators and industry. Ten years later and in anticipation of ICH’s 20th Anniversary, the value and benefits of ICH to regulators have been realized.
  • 2. Mohammad Asim +919953194659 The primary objective of the ICH is to avoid duplicative animal and human testing and to reach a common understanding of the technical requirements to support the registration process in the three ICH regions. These objectives are achieved through harmonized guidelines and result in a more economical use of human, animal and material resources, as well as the elimination of unnecessary delays in the global development and availability of new medicines, whilst maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public health. With the development of the Common Technical Document (CTD), the ICH hopes to accomplish many of its objectives. It is organized into: Module 1: General Information Module 2: CTD summaries Module 3: Quality Module 4: Nonclinical study reports Module 5: Clinical study reports MODULE 1 Administrative information and prescribing information. Document specific to each region. E.g. Application form Proposed label for use in the region
  • 3. Mohammad Asim +919953194659 MODULE 3 QUALITY The Quality section of the Common Technical Document (M4Q) provides a harmonized structure and format for presenting CMC (Chemistry, Manufacturing and Controls) information in a registration dossier. Module 3 content 3.1 Module 3 table of contents 3.2 Body of data 3.3 Literature references MODULE 4: NON-CLINICAL STUDY REPORTS Module 4 describes the format and organization of the nonclinical (pharmaco-toxicological) data relevant to the application. 4.2 STUDY REPORTS 4.2.1 Pharmacology 4.2.2 Pharmacokinetics 4.2.3 Toxicology 4.3 literature references MODULE 5: CLINICAL STUDY REPORTS Module 5 describes the format and organization of the clinical data relevant to the application. 5.3.1 Reports of Biopharmaceutical Studies 5.3.2 Reports of Studies Pertinent to Pharmacokinetics Using Human Biomaterials 5.3.3 Reports of Human Pharmacokinetic (PK) Studies 5.3.4 Reports of Human Pharmacodynamic (PD) Studies 5.3.5 Reports of Efficacy and Safety Studies 5.3.6 Reports of Post-Marketing Experience 5.3.7 Case Report Forms and Individual Patient Listings 5.4 literature references
  • 4. Mohammad Asim +919953194659 ECTD: ELECTRONIC – CTD Developed by M2 EWG (Multidisciplinary 2 Expert Working Group) of ICH. Paper submission has been replaced by electronic submission. CHARACTERISTICS OF ECTD: 1. Files Referenced in the XML Backbone(s) (Extensible Markup Language) REASONS: a) It manages the large data for the entire submission and for each document within the submission. b) This XML backbone allows the eCTD submission to be viewed via a web browser and can be loaded on a Web server. 2. The file formats that can be included in the eCTD are Portable Document Format (PDF) and XML. However other formats can be used for graphs and images. JPEG PNG GIF -may be used for higher resolution. 3. All eCTD submissions include module 1. ADVANTAGES OF CTD  To make the reviewing of each application easier and also to avoid omission of critical data or analyses.  Omissions of such data can result in unnecessary delays in approvals.  To save time and resources.  To facilitate regulatory review and communications.  Appropriate format for the data  Easy to understand and evaluation of data. SILENT BENEFITS OF THE CTD  More “reviewable” applications  Complete, well-organized submissions  More predictable format  More consistent reviews  Easier analysis across applications  Easier exchange of information  Facilitates electronic submissions LIMITATIONS  CTD is only a format, it’s not a single dossier with a single content.  Legal requirements differ in the different regions.  ICH guidelines have not yet harmonized in all requirements.  Pharmacopoeias are not harmonized Applicant may have regional preferences.